Below is a look at some of the headlines for companies that made news in the healthcare sector on October 5, 2010.
Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, announced the publication of an integrated analysis of two randomized placebo-controlled clinical trials with RHUCIN (recombinant human C1 inhibitor, or rhC1INH), in the October issue of the peer reviewed Journal of Allergy and Clinical Immunology (JACI).
The studies were conducted to evaluate the efficacy and safety of two dosage strengths of RHUCIN, an investigational drug, for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema (HAE). HAE is a human genetic disorder in which the patient is deficient in or lacks a functional plasma protein C1 inhibitor, resulting in an overreaction of the immune system.
RHUCIN significantly reduced the time to beginning of relief of symptoms for all anatomical locations studied at both dosage strengths compared to placebo. Lead author Bruce Zuraw, M.D., said, "The publication of the results from these randomized controlled trials is an important step in educating the medical community about recombinant human C1INH for HAE patients with acute angioedema."
Shares rose 19 cents or 6.81% to $2.98.
CEL-SCI Corporation (NYSE: CVM) announced it has received governmental approval from the Hungarian National Institute of Pharmacy to begin enrollment of subjects for a Phase III clinical trial of Multikine in Hungary. Multikine is the Company’s flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Hungary is one of nine countries to participate in this global Phase III trial.
Intellect Neurosciences, Inc. (ILNS.OB), a biopharmaceutical company with internal preclinical and clinical-stage pipelines, as well as multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a patent from the United States Patent and Trademark Office (USPTO) related to its internal Alzheimer's disease (AD) monoclonal antibody program.
The patent is for two highly specific monoclonal antibodies previously acquired by Intellect from Immuno-Biological Laboratories, Ltd. Each of the antibodies binds a different end of the amyloid beta protein without interacting with the amyloid precursor protein from which amyloid beta is generated.
This key safety feature is consistent with the ANTISENILIN monoclonal antibody platform for the prevention and treatment of AD invented by Dr. Daniel Chain, Ph.D., Intellect's Chairman and CEO. Intellect has granted royalty-bearing licenses to several top-tier global pharmaceutical companies with products based on the ANTISENILIN technology, which are in advanced clinical trials involving several thousand AD patients worldwide.
Mylan Inc. (Nasdaq:MYL) announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Atazanavir Sulfate Capsules, 150 mg and 300 mg. This product will be eligible for purchase outside the U.S. in certain developing countries.
Amgen (Nasdaq:AMGN) announced that results from several important studies from the Company's oncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy.
AmStem Corporation (AMST.PK), a leading provider of biotherapeutic and cosmetic stem cell products, stem cell collection and storage expertise and access to nanotechnology vital to stem cell research, announced the appointment of Dr. Michael J. Glantz, M.D. to its Scientific and Medical Board of Advisors (SAMBA).
Apricus Biosciences (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Company has closed its previously announced securities offering, raising over $9.3 million in gross proceeds.
Biomagnetics Diagnostics Corp., (BMGP.PK) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, informed its investors that the Company has significant news pending that it intents to announce over the coming weeks relative to its planned Chinese technology and product acquisitions.
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) will host a Research and Development Day for the investment community on Tuesday, October 19, 2010 from 8:00 a.m. to 12:00 p.m. at the St. Regis Hotel in New York City.
Celgene Corporation (NASDAQ: CELG) announced the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $1.25 billion.
Preclinical data was published on research performed by Cytori Therapeutics (NASDAQ:CYTX) showing adipose (fat)-derived stem and regenerative cells (ADRCs), either fresh or banked, demonstrated statistically significant improvements in animal survival and kidney function in an acute kidney injury animal model.
Daxor Corporation (NYSE: DXR), a medical instrumentation and biotechnology company, today announced that Fresno Heart and Surgical Hospital in Fresno, California has purchased a Blood Volume Analyzer (BVA-100) to assist with the diagnosis and treatment of heart failure patients.
Emerging World Pharma Inc. (EWPI.PK) strategic partner, African Global Pharma (AGP), has completed construction and set up of its generic drug manufacturing facility in Sunyani, Ghana.
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced the publication of preclinical data demonstrating that PEG-SN38 (EZN-2208), the Company’s novel PEGylated DNA topoisomerase I inhibitor, led to significantly greater tumor regression as compared to CPT-11 (irinotecan) in both in vitro and in vivo models of pediatric neuroblastoma.
Express Scripts (Nasdaq:ESRX) has completed the spinoff of its Rx Outreach business unit to create a new independent, nonprofit charitable organization with the mission of improving access to prescription medicines for low-income, uninsured Americans and working families.
Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) will release its third quarter 2010 financial results on Wednesday, November 10, 2010, after the market closes.
Gamma Pharmaceuticals, Inc. (GMPM.PK) Gamma Pharmaceuticals, Inc. announced the expansion of its national distribution network via a comprehensive wholesale distribution agreement with a leading distributor based in Indiana.
GeckoSystems Intl. Corp. (GCKO.PK) announced that they are very pleased with the recent press coverage they have received from Reuters.com.
Geron Corporation (NASDAQ:GERN) announced that GE Healthcare has launched the first human cellular assay product for use in drug discovery and toxicity screening, developed under a license and alliance agreement between the two companies.
Healthmed Services, Ltd. (HEME.PK) is focusing on creating a sales and marketing force to support its revolutionary products and the demand for healthcare technology.
Imaging3™, Inc. (IMGG.OB), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, announced today that the company entered into a Securities Purchase Agreement with two institutional investors for the sale of common stock and warrants for $1 million.
ImmunoCellular Therapeutics (IMUC.OB), a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that the company's clinical data from ICT-107 will be featured in two oral sessions at the World Stem Cell Summit, which is being held October 4-6 in Detroit, MI.
Life Technologies Corporation (NASDAQ:LIFE) announced it will report its third quarter 2010 financial results on Tuesday, October 26, 2010, after market close. The company will also hold a conference call on the same day at 4:30 p.m. EDT to discuss operating results, as well as future expectations.
Mediware Information Systems, Inc. (NASDAQ: MEDW) announced that its hospital-based blood management technologies have successfully enabled the growth of one of the company's most prestigious blood bank customers.
mPhase Technologies, Inc. (XDSL.OB) announced that it has been invited to present at the symposium on "Scalable Energy Storage Beyond Li-Ion: Materials," to be held Oct. 7-8, 2010, at Oak Ridge National Laboratory (ORNL), Oak Ridge, Tennessee.
NuVasive, Inc. (NASDAQ:NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that clinical evidence in support of XLIF® will be prominent at the NASS Meeting this year, which will take place from October 6th through October 8th, 2010, in Orlando, Florida.
Pegasystems Inc. (NASDAQ: PEGA), the leader in Business Process Management (BPM) software solutions and a leading provider of customer relationship management (CRM) solutions, announced several enhancements that address the healthcare industry's critical business imperatives.
PharmaGap Inc. (PHRGF.PK) ("PharmaGap" or "the Company") provided guidance on the Company's clinical development program for its lead cancer drug GAP-107B8 for the fourth quarter 2010 and into 2011.
Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced the publication of an integrated analysis of two randomized placebo-controlled clinical trials with RHUCIN® (recombinant human C1 inhibitor, or rhC1INH), in the October issue of the peer reviewed Journal of Allergy and Clinical Immunology (JACI).
Savanna East Africa, Inc. (OTC:NVAE) has scheduled a Webcast this Friday, October 8th to present a preview of the Company's anticipated activity and events for the 4th calendar quarter of 2010.
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) announced that Silicon Valley Bank (SVB), the primary subsidiary of SVB Financial Group (NASDAQ: SIVB), has increased the existing debt financing facility ("the Bank Line") to the Company's operating subsidiaries.
Simulated Environment Concepts (SMEV.PK), the manufacturer and developer of medical, aesthetic and wellness equipment, announced the company has secured the initial capital required to initiate its plan to reduce manufacturing cost of their flagship product SpaCapsule.
Stellar Pharmaceuticals Inc. (SLXCF.OB) (the "Company") is pleased to announce that subject to regulatory acceptance, the Company is arranging a non-brokered private placement consisting of up to 1,000,000 units of the Company ("Units") at a price of US$1.00 per Unit for gross proceeds of up toUS$1,000,000.
SunLink Health Systems, Inc. (NYSE: SSY) announced that Byron D. Finn has been named President of SunLink ScriptsRx, LLC, the company's specialty pharmacy business.
USANA Health Sciences, Inc. (NASDAQ: USNA) announced that it will present at the Canaccord Genuity Healthy Living Conference in Boston. Jeffrey Yates, Chief Financial Officer, is scheduled to present to leading institutional investment representatives on Wednesday, October 13, 2010, at 8:55 a.m. ET.
UV Flu Technologies, Inc. (UVFT.OB) (the "Company") is pleased to announce that in response to interest from the marketplace, the company intends to rapidly roll out the development of a residential sector air purifier offering features specifically designed for the residential marketplace.
VIVALIS (VLS.PA), a biopharmaceutical company, announced today that it has signed with an undisclosed partner an agreement to evaluate the EB66® cell line for the production of several, undisclosed therapeutic proteins.
Walgreens (NYSE:WAG) had September sales of $5.64 billion, an increase of 5.3 percent from $5.36 billion for the same month in fiscal 2010. Duane Reade stores, acquired in April 2010, contributed 2.8 percentage points to the total sales increase for the month.
Watson Pharmaceuticals, Inc. (NYSE:WPI) confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rasagiline mesylate 0.5 and 1.0 mg tablets.